Bank of America Predicts Up to 240% Jump for These 2 ‘Strong Buy’ Stocks

While PAH is a rare condition, it represents a sizable commercial opportunity. According to Research and Markets, the global PAH market was valued at $8.29 billion in 2024 and is projected to reach nearly $12 billion by 2030, as demand for novel therapies continues to build.The first Bank of America pick we’re looking at is Inhibikase Therapeutics, a small-cap biotech focused on kinase biology, with its current lead effort aimed at pulmonary arterial hypertension, or PAH. It’s a brutal disease driven by pro ...